Cardiovascular Drugs Practice Questions

Q: Which of the following drugs acts as both an arteriolar and venodilator?

Sodium nitroprusside. **Explanation:** Sodium Nitroprusside (SNP) is the correct answer because it acts as a **balanced vasodilator**, affecting both resistance vessels (arterioles) and capacitance vessels (veins) [1, 3]. **Mechanism of Action:** SNP is a prodrug that reacts with hemoglobin to release **Nitric Oxide (NO)** [1]. NO activates guanylyl cyclase, increasing intracellular **cGMP**, which leads to dephosphorylation of myosin light chains and subsequent relaxation of smooth muscles in both arteries and veins. * **Arteriolar dilation** reduces Total Peripheral Resistance (Afterload). * **Venodilation** increases venous pooling and reduces venous return (Preload). **Analysis of Incorrect Options:** * **A. Hydralazine:** A direct-acting **pure arteriolar vasodilator** [1, 2]. It has minimal effect on veins, often leading to significant reflex tachycardia. * **C. Minoxidil:** A potent **arteriolar vasodilator** that works by opening ATP-sensitive $K^+$ channels, causing hyperpolarization of smooth muscle cells [1]. It does not affect veins. * **D. Captopril:** While ACE inhibitors do cause both arterial and venous dilation by reducing Angiotensin II and increasing Bradykinin, they are classified primarily as **balanced vasodilators in the context of chronic therapy**. In the specific context of "vasodilator pharmacology" questions, SNP is the classic prototype for immediate, direct-acting balanced dilation. **High-Yield Clinical Pearls for NEET-PG:** 1. **SNP Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is **Sodium Thiosulfate** or **Hydroxocobalamin**. 2. **Drug of Choice:** SNP is used in hypertensive emergencies but must be protected from light (it is photosensitive). 3. **Steal Phenomenon:** SNP can cause "Coronary Steal," potentially worsening ischemia in patients with CAD. 4. **Minoxidil Side Effect:** Commonly causes **hypertrichosis** (used topically for alopecia) [1].

Q: All of the following statements about the use of spironolactone in CHF are true EXCEPT:

It affords rapid symptomatic relief in CHF patients.. ### Explanation **Spironolactone** is a potassium-sparing diuretic and a Mineralocorticoid Receptor Antagonist (MRA). In Chronic Heart Failure (CHF), its primary role is not acute diuresis, but rather long-term neurohormonal modulation. **1. Why Option D is the Correct Answer (The False Statement):** Spironolactone is a **weak diuretic**. It acts on the distal part of the nephron where only a small fraction of sodium is reabsorbed. Unlike loop diuretics (e.g., Furosemide), it does not produce rapid diuresis or immediate symptomatic relief from pulmonary edema. Its benefits in CHF are primarily due to its ability to prevent myocardial fibrosis and remodeling, which takes weeks to months to manifest. **2. Analysis of Other Options:** * **Option A:** Spironolactone carries a significant risk of **hyperkalemia**, especially when combined with ACE inhibitors. Therefore, it is initiated at low doses (e.g., 12.5–25 mg/day) with close monitoring of serum potassium and creatinine. * **Option B:** Large-scale trials like **RALES** have proven that adding low-dose spironolactone to standard therapy (ACE inhibitors + Digoxin) significantly reduces mortality and morbidity in patients with NYHA Class III and IV heart failure. This is known as "Aldosterone Escape" blockade. * **Option C:** In cases of "diuretic resistance," adding spironolactone can help overcome refractoriness to thiazides or loop diuretics by blocking the compensatory distal sodium reabsorption. **Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist of aldosterone at the Mineralocorticoid Receptor (MR) in the late distal tubule/collecting duct. * **Side Effects:** Hyperkalemia and **Gynecomastia** (due to non-specific binding to androgen and progesterone receptors). **Eplerenone** is a more selective MRA with fewer endocrine side effects. * **Key Trial:** RALES trial (Spironolactone); EMPHASIS-HF trial (Eplerenone).

Q: Which of the following agents decreases cardiac afterload?

Nicorandil. **Explanation:** The correct answer is **Nicorandil** because of its unique dual mechanism of action. To understand this, we must distinguish between **preload** (venous return/venous dilation) and **afterload** (systemic vascular resistance/arterial dilation). 1. **Why Nicorandil is correct:** Nicorandil acts as both a **Nitrate-like vasodilator** and a **K+ATP channel opener**. While the nitrate component causes venodilation (reducing preload), the opening of ATP-sensitive potassium channels leads to significant hyperpolarization of vascular smooth muscle cells in the **arterioles**. This results in potent arterial dilation, which directly decreases systemic vascular resistance, thereby **decreasing cardiac afterload**. 2. **Why other options are incorrect:** * **Glyceryl trinitrate (GTN) & Isosorbide dinitrate:** These are organic nitrates that primarily act on the venous capacitance vessels at therapeutic doses. Their main effect is reducing **preload**. While they can cause some arterial dilation at very high doses, their clinical hallmark is venodilation. Therefore, they are not the primary agents for afterload reduction compared to Nicorandil. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Nicorandil is the only drug in this list that targets both preload and afterload. * **Cardioprotection:** It mimics "ischemic preconditioning" by opening mitochondrial K+ATP channels, protecting the myocardium during ischemia. * **Side Effect Alert:** A classic, high-yield side effect of Nicorandil is **persistent mucosal ulcerations** (anal, oral, or GI ulcers). * **Contraindication:** Like other nitrates, it should not be co-administered with Sildenafil (PDE-5 inhibitors) due to the risk of severe hypotension.

Q: Which of the following drugs does NOT reduce myocardial remodelling in Congestive Heart Failure?

Digoxin. **Explanation:** The goal of modern Heart Failure (HF) management is to block the neurohormonal compensatory mechanisms (Sympathetic and RAAS activation) that lead to **myocardial remodelling**—the structural changes (hypertrophy, fibrosis, and ventricular dilation) that worsen cardiac function over time. **Why Digoxin is the correct answer:** Digoxin is a positive inotropic agent that inhibits the Na+/K+ ATPase pump. While it improves symptoms and reduces the rate of hospitalization by increasing cardiac contractility, it has **no effect on the neurohormonal pathways** responsible for structural remodeling. Consequently, Digoxin does not reduce mortality in heart failure patients. **Analysis of other options:** * **Carvedilol (Beta-blocker):** Blocks the chronic effects of catecholamines, preventing apoptosis and cardiac hypertrophy. Beta-blockers are cornerstones in reducing mortality and reversing remodeling. * **Enalapril (ACE Inhibitor):** Prevents the formation of Angiotensin II, a potent stimulus for myocyte growth and collagen deposition. ACE inhibitors are the first-line agents for preventing remodeling. * **Spironolactone (Mineralocorticoid Receptor Antagonist):** Blocks aldosterone, which is directly responsible for myocardial and vascular fibrosis. It significantly reduces mortality in NYHA Class II-IV heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs reducing mortality in HF:** ACE inhibitors, ARBs, Beta-blockers (specifically Carvedilol, Metoprolol succinate, Bisoprolol), Aldosterone antagonists, and SGLT2 inhibitors. * **Drugs improving symptoms but NOT mortality:** Digoxin and Diuretics (Furosemide). * **Digoxin Toxicity:** Characterized by gastrointestinal symptoms, xanthopsia (yellow vision), and any arrhythmia (most common: PVCs; most specific: PAT with block).

Q: Which of the following drugs is NOT used to reverse cardiac remodeling in congestive cardiac failure?

Digoxin. **Explanation:** Cardiac remodeling is the structural change in the heart (hypertrophy, fibrosis, and chamber dilation) driven by chronic neurohumoral activation. To reverse or prevent this, a drug must inhibit the **Sympathetic Nervous System (SNS)** or the **Renin-Angiotensin-Aldosterone System (RAAS)**. **Why Digoxin is the correct answer:** Digoxin is a positive inotrope that acts by inhibiting the Na+/K+ ATPase pump. While it improves symptoms and reduces hospitalization rates in heart failure (HF), it has **no effect on cardiac remodeling** and does not reduce mortality. It is primarily used for rate control in patients with concomitant Atrial Fibrillation or for symptomatic relief in refractory HF. **Why the other options are incorrect:** * **ACE Inhibitors (e.g., Enalapril):** These are the gold standard for reversing remodeling. They decrease Angiotensin II levels, reducing fibroblast proliferation and cardiac hypertrophy. * **Beta Blockers (e.g., Carvedilol, Metoprolol):** They counteract the toxic effects of chronic catecholamine exposure, allowing the heart to recover its systolic function over time (reverse remodeling). * **Aldosterone Antagonists (e.g., Spironolactone):** These prevent aldosterone-induced myocardial fibrosis and collagen deposition, significantly reducing mortality in NYHA Class II-IV heart failure. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mortality-Reducing Drugs in HF:** ACEIs, ARBs, Beta-blockers, Aldosterone antagonists, and ARNIs (Sacubitril/Valsartan). 2. **Digoxin Toxicity:** Characterized by xanthopsia (yellow vision) and various arrhythmias; the most characteristic is **Paroxysmal Atrial Tachycardia with AV block**. 3. **ARNI:** Currently considered superior to ACEIs for reversing remodeling in HFrEF.

Q: Which of the following calcium channel blockers is useful in the treatment of supraventricular tachycardia by suppressing AV node conduction?

Verapamil. Explanation: Calcium channel blockers (CCBs) are broadly classified into two categories: **Dihydropyridines (DHPs)** and **Non-Dihydropyridines (Non-DHPs)** [1]. **Why Verapamil is correct:** Verapamil is a Non-DHP CCB with significant **cardioselective** properties. It primarily acts on the L-type calcium channels in the myocardium and the conduction system [3]. By blocking these channels in the **Atrioventricular (AV) node**, it increases the refractory period and slows down conduction velocity (negative dromotropy) [3]. This makes it highly effective for terminating and controlling the ventricular rate in **Supraventricular Tachycardia (SVT)** [3]. **Why the other options are incorrect:** * **Amlodipine and Nifedipine:** These are Dihydropyridines. They are **vasoselective**, acting primarily on smooth muscles of the peripheral blood vessels to cause vasodilation [1]. They have minimal effect on the AV node at clinical doses and may even cause reflex tachycardia, making them unsuitable for arrhythmias [4]. * **Nimodipine:** This is a DHP with high lipid solubility and selectivity for **cerebral blood vessels**. It is specifically used to prevent cerebral vasospasm following subarachnoid hemorrhage, not for cardiac arrhythmias [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Adenosine is the DOC for acute paroxysmal SVT; Verapamil is an alternative [3]. * **Contraindication:** Never give Verapamil in wide-complex tachycardia of unknown origin or in WPW syndrome with Atrial Fibrillation, as it may precipitate ventricular fibrillation [2]. * **Side Effects:** Constipation is the most common side effect of Verapamil [2]. * **Diltiazem:** Another Non-DHP CCB (Benzothiazepine) that acts on both the heart and blood vessels, also used in SVT [3].

Q: Ankle edema caused by calcium channel blockers is prevented by which of the following classes of drugs?

ACE inhibitors. **Explanation:** The ankle edema associated with **Dihydropyridine Calcium Channel Blockers (CCBs)** like Amlodipine is not due to fluid overload, but rather a result of **preferential precapillary (arteriolar) vasodilation**. This increases the hydrostatic pressure in the capillaries, causing fluid to leak into the interstitial space. **1. Why ACE inhibitors are correct:** ACE inhibitors (and ARBs) cause **balanced vasodilation** of both the **precapillary (arteriolar)** and **postcapillary (venular)** vessels. By dilating the venules, ACE inhibitors reduce the hydrostatic pressure gradient in the capillary bed, thereby facilitating the reabsorption of fluid back into the vascular compartment and neutralizing the edema caused by CCBs. **2. Why other options are incorrect:** * **Propranolol:** This is a non-selective beta-blocker. While it can be used to treat reflex tachycardia caused by CCBs, it has no significant effect on postcapillary venodilation and does not prevent peripheral edema. * **Adrenaline:** This is a sympathomimetic. It would likely worsen cardiovascular parameters and has no role in managing drug-induced edema. * **Ropinirole:** This is a dopamine agonist used in Parkinson’s disease and Restless Leg Syndrome. Interestingly, Ropinirole itself is known to *cause* peripheral edema as a side effect. **Clinical Pearls for NEET-PG:** * **Mechanism:** CCB-induced edema is "non-pitting" and does not respond to diuretics (like Furosemide) because the total body sodium/water is normal. * **Combination Therapy:** The combination of a CCB and an ACE inhibitor is a "high-yield" clinical strategy because it provides synergistic BP lowering while minimizing the side effect of edema. * **Other CCB side effects:** Gingival hyperplasia, reflex tachycardia (with DHPs), and constipation (specifically Verapamil).

Q: What is the drug of choice for maintenance in paroxysmal supraventricular tachycardia (PSVT)?

Adenosine. **Explanation:** **Adenosine** is the drug of choice for the **acute termination** of Paroxysmal Supraventricular Tachycardia (PSVT). Its mechanism involves the activation of $A_1$ receptors on the AV node, which increases potassium efflux and inhibits calcium influx. This leads to profound hyperpolarization and a transient "chemical cardioversion" by slowing conduction through the AV node, effectively breaking the re-entrant circuit. **Analysis of Options:** * **Adenosine (Correct):** It has an ultra-short half-life (<10 seconds), making it ideal for rapid termination of PSVT with minimal systemic side effects. * **Amiodarone:** A Class III antiarrhythmic used primarily for ventricular arrhythmias and atrial fibrillation. It is not the first-line choice for PSVT due to its slow onset and extensive side-effect profile. * **Lignocaine:** A Class IB sodium channel blocker. It is effective only for **ventricular arrhythmias** (post-MI) and has no efficacy in supraventricular arrhythmias like PSVT. * **Verapamil:** A Calcium Channel Blocker (Class IV). While it can be used for PSVT, it is considered a second-line agent compared to Adenosine because it causes more prolonged hypotension and has a slower onset of action. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** Adenosine must be given as a **rapid IV bolus** (usually 6mg followed by 12mg) through a large-bore peripheral vein, followed by a saline flush, due to its rapid metabolism by erythrocytes and vascular endothelial cells. * **Contraindications:** Avoid in patients with **Asthma** (may cause bronchospasm) and **High-degree AV block**. * **Drug Interactions:** The effects of Adenosine are **potentiated by Dipyridamole** and **antagonized by Theophylline/Caffeine** (adenosine receptor blockers). * **Side Effects:** Patients often experience a transient sense of "impending doom," chest pain, or flushing.

Q: All of the following drugs belong to Class 1 antiarrhythmic drugs except?

Propanolol. **Explanation:** The classification of antiarrhythmic drugs is based on the **Vaughan Williams Classification**, which categorizes drugs according to their primary mechanism of action on the cardiac action potential. **Why Propranolol is the correct answer:** Propranolol is a non-selective beta-adrenergic blocker. According to the Vaughan Williams classification, beta-blockers belong to **Class II**. They work by inhibiting sympathetic stimulation, decreasing the slope of Phase 4 depolarization in pacemaker cells (SA and AV nodes), thereby reducing heart rate and conduction velocity. **Analysis of Incorrect Options (Class I Drugs):** Class I drugs are primarily **Sodium (Na+) channel blockers** that decrease the rate of Phase 0 depolarization. They are subdivided into three groups: * **Option A (Quinidine) & Option B (Procainamide):** These belong to **Class IA**. They moderately block Na+ channels and also block K+ channels, which prolongs the action potential duration (APD) and the QT interval. * **Option C (Flecainide):** This belongs to **Class IC**. It is a potent Na+ channel blocker with minimal effect on APD. It significantly slows conduction and is used for supraventricular arrhythmias in patients without structural heart disease. **High-Yield NEET-PG Pearls:** * **Class IB (e.g., Lidocaine, Mexiletine):** These shorten the APD and are specifically effective for ventricular arrhythmias, especially post-Myocardial Infarction. * **Class III (e.g., Amiodarone, Sotalol):** These are Potassium (K+) channel blockers that prolong Phase 3 repolarization. * **Class IV (e.g., Verapamil, Diltiazem):** These are Calcium (Ca2+) channel blockers. * **Mnemonic for Class I:** "**D**ouble **Q**uarter **P**ounder, **L**ettuce **M**ayo **T**omato, **F**ries **P**lease" (**IA:** **D**isopyramide, **Q**uinidine, **P**rocainamide; **IB:** **L**idocaine, **M**exiletine, **T**ocainide; **IC:** **F**lecainide, **P**ropafenone).

Question 1

Which of the following drugs acts as both an arteriolar and venodilator?

Accepted Answer

Sodium nitroprusside

Answer

Hydralazine

Answer

Minoxidil

Answer

Captopril

Question 2

All of the following statements about the use of spironolactone in CHF are true EXCEPT:

Accepted Answer

It affords rapid symptomatic relief in CHF patients.

Answer

It should be administered in low doses to prevent hyperkalemia.

Answer

It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors.

Answer

It helps to overcome the refractoriness to thiazides.

Question 3

Which of the following agents decreases cardiac afterload?

Accepted Answer

Nicorandil

Answer

Glyceryl trinitrate

Answer

Isosorbide dinitrate

Answer

None of the above

Question 4

Which of the following drugs does NOT reduce myocardial remodelling in Congestive Heart Failure?

Accepted Answer

Digoxin

Answer

Carvedilol

Answer

Enalapril

Answer

Spironolactone

Question 5

Which of the following drugs is NOT used to reverse cardiac remodeling in congestive cardiac failure?

Accepted Answer

Digoxin

Answer

Beta blocker

Answer

ACE inhibitor

Answer

Aldosterone antagonist

Question 6

Which of the following calcium channel blockers is useful in the treatment of supraventricular tachycardia by suppressing AV node conduction?

Accepted Answer

Verapamil

Answer

Amlodipine

Answer

Nimodipine

Answer

Nifedipine

Question 7

Ankle edema caused by calcium channel blockers is prevented by which of the following classes of drugs?

Accepted Answer

ACE inhibitors

Answer

Propranolol

Answer

Adrenaline

Answer

Ropinirole

Question 8

What is the drug of choice for acute left ventricular failure?

Accepted Answer

Intravenous Furosemide

Answer

Rapid digitalization

Answer

Intravenous Aminophylline

Answer

Intravenous Morphine

Question 9

What is the drug of choice for maintenance in paroxysmal supraventricular tachycardia (PSVT)?

Accepted Answer

Adenosine

Answer

Amiodarone

Answer

Lignocaine

Answer

Verapamil

Question 10

All of the following drugs belong to Class 1 antiarrhythmic drugs except?

Accepted Answer

Propanolol

Answer

Quinidine

Answer

Procainamide

Answer

Flecainide

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?